Suppr超能文献

以色列的“绿色通行证”政策经验凸显了其他国家决策者需要考虑的问题。

The Israeli Experience with the "Green Pass" Policy Highlights Issues to Be Considered by Policymakers in Other Countries.

机构信息

Department of Health Care Management, Faculty of Economics & Management, Technische Universität, 10623 Berlin, Germany.

Department of Health Policy and Management, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.

出版信息

Int J Environ Res Public Health. 2021 Oct 26;18(21):11212. doi: 10.3390/ijerph182111212.

Abstract

In the first half of 2021, Israel had been ahead of other countries concerning the speed of its rollout and coverage of COVID-19 vaccinations. During that time, Israel had implemented a vaccine certificate policy, the "Green Pass Policy" (GPP), to reduce virus spread and to allow the safe relaxation of COVID-19 restrictions in a time of great uncertainty. Based on an analysis of GPP regulations and public statements compiled from the Israeli Ministry of Health website, we describe the design and implementation of the GPP. We also look back and discuss lessons learned for countries that are considering a GPP policy, given the current upsurge of the Delta variant as of summer 2021. To reduce equity concerns when introducing a GPP, all population groups should be eligible for the vaccine (contingent on approval from the manufacturer) and have access to it. Alternatively, health authorities can grant temporary certificates based on a negative test. We also highlight the fact that in practice, there will be gaps between the GPP regulations and implementation. While some places might require a GPP without legal need, others will not implement it despite a legal obligation. The GPP regulations should have standardised epidemiological criteria, be implemented gradually, remain flexible, and change according to the epidemiological risks.

摘要

2021 年上半年,以色列在新冠疫苗接种速度和覆盖范围方面领先于其他国家。当时,以色列实施了疫苗证书政策,即“绿色通行证政策”(GPP),以减少病毒传播,并在充满不确定性的时期安全放宽对新冠的限制。基于对 GPP 法规和从以色列卫生部网站上汇编的公开声明的分析,我们描述了 GPP 的设计和实施。鉴于 2021 年夏季德尔塔变异株的爆发,我们还回顾并讨论了对正在考虑 GPP 政策的国家的经验教训。为了在引入 GPP 时减少公平性问题,所有人群都应符合接种疫苗的条件(取决于制造商的批准)并能获得疫苗。或者,卫生当局可以根据阴性检测结果授予临时证书。我们还强调了一个事实,即实际上,GPP 法规和实施之间会存在差距。虽然有些地方可能不需要法律上的 GPP,但其他地方尽管有法律义务也不会实施 GPP。GPP 法规应具有标准化的流行病学标准,应逐步实施,保持灵活性,并根据流行病学风险进行调整。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f684/8582817/4dbab83ff5d1/ijerph-18-11212-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验